Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2008

View Archived Issues

Phynova announces collaboration agreement with Norgine in liver disease

Metabolon and Joslin Diabetes Center to collaborate in area of insulin resistance and diabetes

Hemispherx enters major contract with Lovelace Respiratory Research Institute

Zacharon completes Series A Financing to advance glycan inhibitor program

Infinity enters alliance with Purdue and Mundipharma for early clinical and discovery programs

Novel tachykinin NK1 receptor antagonists divulged in recent Merck & Co. patent

Recent GSK patent claims new 5-HT1A receptor antagonists for premature ejaculation

Novel therapeutic agents for cancer cachexia and muscle wasting imparted in recent Santhera patent

Neuromed completes enrollment for phase III trial of NMED-1077 in chronic low back pain

Biofrontera completes enrollment in phase II study of BF-derm1 in severe chronic urticaria

Cosmo and Dr. Falk sign licensing agreement for Rifamycin SV MMX

Avexa completes recruitment for first component of phase III trial of apricitabine

ChemDiv and Avineuro extend collaboration in Alzheimer's disease

Johnson & Johnson enter into definitive agreement to acquire Omrix

DepoMed enters into exclusive license agreement with Solvay for DM-1796

CHMP recommends refusal of Bristol-Myers' marketing authorization for Ixempra

CHMP recommends extension to Janssen-Cilag's marketing authorization for Prezista

Bristol-Myers exercises option to develop and commercialize Exelixis' XL-413

Medarex initiates phase Ib clinical trial of MDX-1106 in cancer

Antares and Population Council initiate phase II contraceptive ATD Gel trial

MK-677 does not meet efficacy endpoints in a phase II Alzheimer's disease study

UWA-0121 extends L-DOPA activity in primate model of Parkinson's disease

Hematide safe over the long term in chronic kidney disease patients

Antiallodynic activity of Adolor's novel potent NGF-TrkA antagonist

Preliminary phase II results show activity of GI-5005-containing therapy in HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...